Clinical efficacy of daratumumab

Evaluation of Daratumumab for the Treatment of Multiple Myeloma ...

The addition of daratumumab to backbone multiple myeloma regimens was associated with significantly improved progression-free survival among ...

Meta-analysis of the efficacy and safety of daratumumab in the ...

Core Tip: Daratumumab demonstrates promising efficacy in treating multiple myeloma, improving the overall response rate, complete remission, and ...

Efficacy and safety of daratumumab in the treatment of multiple ...

The available evidence demonstrated that the clinical application of combination regimens containing daratumumab improved the efficacy in patients with MM and ...

Teclistamab Plus Daratumumab Shows Improved Clinical Efficacy in ...

The combination of teclistamab and daratumumab may improve clinical efficacy, according to longer follow-up data from the phase Ib TRIMM-2 study.

Daratumumab in Indian Patients with Relapsed and Refractory ...

This prospective, multicenter, pragmatic, phase IV study evaluated the safety and efficacy of daratumumab monotherapy during routine clinical practice in Indian ...

DARZALEX® (daratumumab) Relapsed or Refractory Trials

View clinical trial information for DARZALEX® relapsed or refractory patients, including study design, efficacy, and safety. See full Prescribing & Safety ...

Comparative Efficacy of Daratumumab Monotherapy and ...

This matching adjusted indirect comparison of clinical trial data from four studies analyzes the survival outcomes of patients with heavily pretreated, relapsed ...

Daratumumab Combination Therapy Improved Clinical Outcomes ...

According to follow-up data from the POLLUX study, daratumumab (D), in combination with lenalidomide (an immunomodulatory agent) and ...

Clinical Trials - Mayo Foundation for Medical Education and Research

The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at ...

Efficacy and safety of daratumumab with dexamethasone in patients ...

Conclusion: DARA plus dexamethasone was efficacious with a favorable safety profile in pts with RRMM and severe RI or requiring dialysis. Hematologic responses ...

A SINGLE-CENTER PHASE 2 OPEN-LABEL TRIAL

Conclusion: Daratumumab induced a therapeutically relevant reduction of pathogenic anti-dsDNA antibodies in SLE with a favorable safety profile. Clinical ...

Subcutaneous daratumumab in patients with relapsed or refractory ...

In clinical studies of daratumumab, the median durations of the first, second, and subsequent daratumumab IV infusions were 7.0, 4.3, and 3.4 hours (h), ...

Darzalex, INN-daratumumab - European Medicines Agency

The new analyses presented do not change the current knowledge on PK/PD and immunogenicity of daratumumab. 2.4. Clinical efficacy. 2.4.1. Dose ...

Impressive Results With Daratumumab Plus Lenalidomide ...

Dr. Plesner updated the safety and efficacy data from the ongoing phase I/II GEN503 trial of daratumumab in combination with lenalidomide/ ...

DARZALEX FASPRO ® non-inferiority trial vs DARZALEX ® IV

In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO® as ...

761036Orig1s000 - accessdata.fda.gov

... measured in clinical pharmacology and clinical studies? Trial MMY2002 was the key registration trial to establish the efficacy and safety of daratumumab, with.

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in ...

Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. Contact Us. For more ...

Daratumumab Combo Sparks 81% Response Rate in Myeloma

The efficacy combined with a favorable safety profile point to the potential for incorporating daratumumab into existing and emerging multiple ...

Daratumumab monotherapy in patients with treatment-refractory ...

reported efficacy of daratumumab 16 mg/kg mono- therapy in relapsed ... 002 clinical trial (2% of patients with at least a very good. PR) ...

Efficacy and safety of daratumumab plus bortezomib and ...

Agents targeting the deposited amyloid fibrils on affected organs are appealing, but not ready for routine clinical practice. ... Thus, the ...